All News
Dr. Jonathan Kay with changes in ICD coding from ICD-9 to ICD-10.
And we just got an ICD code for nr-axSpA!
It's M46.80
https://t.co/JAlF4ERoHr
#ACR20 https://t.co/lmElQVtv35
Rheum Cat rheum_cat ( View Tweet)
Billing and coding is important! Trying to learn more at #ACR20 #3S017😖 Common pitfalls noted here @RheumNow New 2021 EM CPT coding comin soon- so things will have to be relearned..:( [PE will go away from billing requirements??]😐 https://t.co/GeBxQ0lb8l
Bella Mehta bella_mehta ( View Tweet)
Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the classification of axSpA. Do you think it’s time to change our nomenclature and classification criteria? #ACR20 @RheumNow https://t.co/YJcvLKnyFy
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS criteria. This likely won’t be adopted in the US for several years. #ACR20 @RheumNow https://t.co/oDhs1EHSTP
Dr. Rachel Tate uptoTate ( View Tweet)
Is it time to change RA EULAR guidelines to reflect what we do? SEAM RCT showed withdrawal of MTX better than D/C etanercept in controlled RA. ETN alone =ETN+MTX. I vote to d/c the Rx that failed or by pt preference! Abstr#939 @RheumNow #ACR20 https://t.co/l9TNM3Gt0e
Janet Pope Janetbirdope ( View Tweet)
Dr. V. Liarski reviews 11 pearls for billing and coding in #ACR20 @RheumNow my favorite takeaway is #11 good billing does not equal good medical practice and vice versa! https://t.co/M7yMMoFwwD
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow #acr20 abs0600 a case control stdy of 545 CHF exacerbate admissions: pts w/gout flares median LoS 10 d vs 6 d w/out flare or gout at all. log LoS w gout flare 2.41 ± 0.96 vs 1.77 ± 0.90 w/out, p < 0.0001. Prevention of gout flares in CHF pts of essence #ACRbest https://t.co/8xiHHYxvsC
Olga Petryna DrPetryna ( View Tweet)
Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was an important US rheumatologist who did NOT believe AS was a separate disease entity from RA! It wasn't until his death that the college recognized both separately! @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq
Eric Dein ejdein1 ( View Tweet)
@RheumNow #acr20 abs0654 we are what we eat: analysis of OmniHeart trial of pts w/HTN reveals DASH-patterns plant-based protein diet can also significantly lower sUA improves HTN &hyperlipidemia. Clincial trial of DASH plant protein based diet in gout would be interesting. https://t.co/5tQwiuwl84
Olga Petryna DrPetryna ( View Tweet)
Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Curtis presents SEAM-RA RCT of withdrawal of ETN or MTX in patients on combo therapy in sustained remission. 49.5% of ETN mono retained remission compared to 28.7% of MTX mono, and 52.9% who continued combo therapy. @rheumnow #ACR20 Abstr#939 #ACRbest https://t.co/wpAtBHJYUF
Richard Conway RichardPAConway ( View Tweet)
Low pre🤰c3/c4 levels assoc'd w/ ⬆ risk of adverse obstetric outcomes in women w/ aPL w/or w/o APS. Pts w/ triple+ aPL and ⬇ c3/c4 predicts a worse prognosis. @RheumNow #ACR20 https://t.co/Cd2TQBfXSe
sheila RHEUMarampa ( View Tweet)
@RheumNow #acr20 abs 0649 PROTECT trial of pegloticase in 7 kidney transplant pts w/uncontrolled gout: 2-12 infusions, 2+immunosuppressants on board for transplant care. No change in eGFR, HAQ pain ⬇️by 33.8 at wk20. Alb/cr improved by >35%in 2pts. sUA< 1 mg/dL, no serious AEs https://t.co/f4tnFjMTe8
Olga Petryna DrPetryna ( View Tweet)
#myositis & the ❤: lab tests
⬆ Trop = myocardial stress & injury, absence doesn't r/o myocarditis
BNP - utility unclear
There are no biomarkers specific for myocardial involvement
@RheumNow #ACR20 https://t.co/eyihKPoXSc
sheila RHEUMarampa ( View Tweet)
Does your pt have myocardial inflamm? Trop specific but not sensitive, BNP neither sens or specific. Consider EKG - sensitive (85%), but non-specific- But TTE is essential and cMRI is best! #ACR20 @RheumNow Great lecture from cardiologist, @HopkinsBayview APD https://t.co/6THm37KbQ3
Eric Dein ejdein1 ( View Tweet)
What happens long-term in Kawasaki disease now? Has IVIG availability fixed this?
Pop-based cohort, long follow-up.
Turns out cardiac event risk, whilst greatest early, continues >10y after - even in those w/o coronary aneurysms
@SickKidsNews @McMasterU #ACR20 ABST0937 @RheumNow https://t.co/1T6JmwhXNb
David Liew drdavidliew ( View Tweet)
Listen to part I of our #ACR20 Day 1 recap. Listen through the link below or find us on Apple podcasts.
https://t.co/W6EMQiF9Rf https://t.co/R1ieCFnIxz
Links:
Dr. John Cush RheumNow ( View Tweet)
Health plan claims data appears useful to classify inadequate responders in PsA and should be studied further. #ABS0898 #ACR20 @RheumNow https://t.co/jXBr54Fc6Z https://t.co/fAESyo5Uad
Dr. Rachel Tate uptoTate ( View Tweet)